Why Regeneron Pharmaceuticals Dropped 11.3% in September
Despite sharing a series of positive news items with investors, shares of biotech-giant Regeneron Pharmaceuticals (NASDAQ: REGN) fell more than 11% in September, according to data from S&P Global Market Intelligence.
Regeneron and its partner Sanofi (NYSE: SNY) made a number of announcements during the month that captured the market's attention.
Here's an overview of the key developments from the month:
Source: Fool.com
Sanofi S.A. ADR Stock
€38.40
0.530%
Currently there is a rather positive sentiment for Sanofi S.A. ADR with 4 Buy predictions and 0 Sell predictions.
As a result the target price of 49 € shows a positive potential of 27.6% compared to the current price of 38.4 € for Sanofi S.A. ADR.
